On April 1, 2021 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, reported it will participate in two virtual investor conferences in April 2021 (Press release, Aeglea BioTherapeutics, APR 1, 2021, View Source [SID1234577543]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access Day
Conference Date: Tuesday, April 6 and Thursday, April 8
Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Michael C. Hanley, Aeglea’s chief commercial officer

Conference Name: 20th Annual Needham Virtual Healthcare Conference
Conference Date: Monday, April 12 through Thursday, April 15
Presentation Date and Time: Tuesday, April 13 at 11:00 am ET
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Webcast: View Source

To access the live and archived webcast, visit the Events & Presentations section of the Company’s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. A replay of the webcast will be available through the Company’s website for 30 days thereafter.

On April 1, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that management will participate in 1×1’s at investor conferences through April 2021 (Press release, Autolus, APR 1, 2021, View Source [SID1234577542]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

April 6 and 8, 2021 – Wells Fargo Annual Biotech Corporate Access
April 14, 2021 – 20th Annual Needham Virtual Healthcare Conference – As well as 1×1’s, the CEO and CFO will participate in a Fireside Chat at 10:15 AM ET. A webcast of the Fireside Chat will be available on the investor relations section of the Company’s website at Autolus.
April 22, 2021 – Raymond James Oncology Summit
April 28, 2021 – Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day

On April 1, 2021 AbCellera (Nasdaq: ABCL) reported agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse (Press release, AbCellera, APR 1, 2021, View Source [SID1234577539]). Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by AbCellera under this collaboration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Building on the successful completion of the first collaboration together, under the new agreement AbCellera will generate panels of antibodies for up to eight new targets, across multiple indications, selected by Gilead. The expanded collaboration will leverage the full breadth of AbCellera’s technology stack, including the recently added capabilities for sourcing diverse, fully-humanized antibodies using the Trianni Mouse platform and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform.

"We are excited to build on the success of the first program and deepen our relationship with the team at Gilead," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are particularly pleased to see the value created for our partners by quickly integrating the Trianni Mouse and OrthoMabTM platforms, which we acquired in second half of 2020."

AbCellera’s partners benefit from an operating system designed to support many antibody modalities, unlock new targets, and increase the speed and the probability of success of their therapeutic antibody discovery programs. AbCellera’s AI-powered technology stack brings together microfluidics, single cell analysis, machine learning, computation, custom robotics, and automation to compound the power of each step in the discovery process.

On April 1, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reported that Aoife Brennan, M.B. Ch.B., Synlogic’s President and Chief Executive Officer, and other members of the executive team will present at the following virtual banking and industry conferences (Press release, Synlogic, APR 1, 2021, View Source [SID1234577534]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20th Annual Needham Virtual Healthcare Conference: Dr. Brennan and Daniel Rosan, SVP & Head of Finance, will present at 3:00 pm on Monday, April 12, 2021.
Jefferies Microbiome-based Therapeutics Summit: Dr. Brennan will participate in a Fireside Chat that will become available on Thursday, April 22, 2021.
These are virtual events. A live webcast of the presentations, if available, can be accessed under "Event Calendar" in the Investors & Media section of the Company’s website. An archived copy of the webcast will be available on the Synlogic website for approximately 30 days after the event.

On April 1, 2021 Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, reported the sale of its minority share in Q2 Solutions to IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, for $760 million in an all-cash transaction (Press release, Quest Diagnostics, APR 1, 2021, View Source [SID1234577533]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q2 Solutions is a leading global clinical laboratory services organization that provides comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions for clinical trials. IQVIA and Quest established Q2 Solutions as a joint venture in 2015. IQVIA previously owned a 60 percent majority share and Quest Diagnostics owned a 40 percent minority share.

"Divesting from Q2 Solutions supports our vision to be focused on empowering better health with diagnostic information services," said Steve Rusckowski, Quest Diagnostics Chairman, CEO and President. "We are proud of our contributions to the growth of Q2 Solutions, and are confident that IQVIA has the strategic vision and agility to lead Q2 Solutions on the next phase of its journey as a global leader in central lab services."

Under a multi-year agreement, Quest will remain the strategic preferred laboratory provider for Q2 Solutions’ clients, providing a range of complementary lab testing capabilities to augment Q2 Solutions’ core offerings and extend its industry leading suite of services.